Capstone Investment Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Capstone Investment Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,200	Closed	-$2.46M	–	1880
2025 Q4	$2.46M	Buy	+20,200	New	+$2.32M	﹤0.01%	551
2024 Q4	–	Sell	-75,000	Closed	-$7.41M	–	2038
2024 Q3	$7.41M	Buy	+75,000	New	+$7.37M	0.02%	364
2023 Q3	–	Sell	-30,000	Closed	-$2.5M	–	2314
2023 Q2	$2.5M	Buy	+30,000	New	+$2.51M	0.01%	577
2021 Q3	–	Sell	-76,000	Closed	-$10.3M	–	2079
2021 Q2	$10.3M	Buy	+76,000	New	+$9.99M	0.02%	527

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Capstone Investment Advisors's XBI Position: Q1 2026 in Review

Capstone Investment Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 16% in Q1 2026, buying an estimated $982K and bringing the position to 57,915 shares worth $7.4M. The position accounts for 0.01% of the portfolio, ranked #348.

Capstone Investment Advisors first reported a position in XBI in Q2 2021 and has held it in 14 quarters since. The position peaked at $9.87M in Q4 2021. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Capstone Investment Advisors held 57,915 shares of State Street SPDR S&P Biotech ETF worth $7.4M as of Q1 2026.
Capstone Investment Advisors bought 7,864 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $982K.
State Street SPDR S&P Biotech ETF made up 0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #348 holding.
Capstone Investment Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and has held it in 14 quarters since.
Capstone Investment Advisors's State Street SPDR S&P Biotech ETF position peaked at $9.87M in Q4 2021.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.